Navigation Links
Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
Date:4/29/2008

ence of HAIs. Because infection incidence is measured consistently with the NIM, comparisons among hospitals are a meaningful way to identify best practices and focus resources where they have the highest likelihood of reducing HAIs.

"Knowing that East Alabama Medical Center is among the best in the state for infection prevention performance validates the effort we have put behind patient safety initiatives that have reduced infections across our hospital," said Benja Morgan, infection control and employee health manager of East Alabama Medical Center. "But the real benefit from the benchmarking tool is in knowing how other hospitals perform and sharing knowledge and best practices to ensure continued improvement."

MedMined(TM) services launched the benchmarking tool in February as an additional feature for 46 hospitals in Alabama. The new tool will be discussed in detail at the Alabama Quality Forum, being held today in Birmingham, Ala. in conjunction with the Alabama Hospital Quality Initiative (AHQI) best practice meeting. AHQI is a partnership between MedMined(TM) services, Blue Cross and Blue Shield of Alabama and the Alabama Hospital Association. Members of the Alabama Hospital Association's Quality Task Force as well as Infection Control Professionals from Alabama's Association for Professionals in Infection Control (APIC) group worked for more than a year with MedMined(TM) services to provide input into the design of the benchmarking system.

The benchmarking capability will be rolled out to hospitals across the country that use MedMined(TM) services in a phased approach starting in May, and will become part of the standard package at no additional fee.

"Understanding a true hospital-wide view of HAIs is the first step to improving infection prevention," said Patrick Hymel, M.D., vice president and general manager of Cardinal Health's MedMined(TM) services. "The MedMined(TM) benchmarking tool is a big step forward in allowing best
'/>"/>

SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
6. Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs. Angiographic Guidance of Stent Deployment in Patients with Multivessel Disease
7. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
11. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...karia Holdings, Inc. today announced that it has b...ersey Technology Council (NJTC), a 1,200-member no...rt, networking opportunities, information and advo...karia earned the award based on criteria including...ision. , , "We are delighted that the New J...
(Date:11/20/2008)...T PHASE III TRIAL SHOW SIGNIFICANT, DECREASES...CTION, IN, FIBROMYALGI... Belgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz ...uronext Brussels: UCB),announced today positive p...,Phase III pivotal clinical trials of sodium oxyba...
(Date:11/20/2008)...- Radius Health ("Radius") announced today that it...d institutional financing round, increasing total ... amount raised since the company,s inception to $1... participated in the financing, led by MPM Bio IV ...Wellcome Trust, HealthCare Ventures, Oxford Biosci...
(Date:11/19/2008)...re-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mill...of,Takeda Pharmaceutical Company Limited (TSE: 40... 3 MONET1 trial evaluating motesanib (AMG 706) in,...he first-line treatment of,advanced non-small cel...ed,following a planned safety data review of 600 ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 1Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 2Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 3Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 4Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 5Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 6Regular tipple may curb risk of rheumatoid arthritis 21104 1Regular tipple may curb risk of rheumatoid arthritis 21104 2Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 1Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 1MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 3
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)... Va., Nov. 21 The Gener... following statement today from,GPhA President an...Commission,(FTC) roundtable on "Emerging Health C...e mere fact that the FTC is conducting this roundt...uring that consumers have access to safe and,affo...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2
...armaceuticals Inc (RPI) has received a tentative a...sinopril is recommended for hypertension, either a...anti-hypertenive agents. It is also used as adjunc...t failure and patients who do not respond to diure...
...s of drugs based on a widely used anticancer drug,...fects in the laboratory and in mice, according to ...eresting for the treatment of these tumors. // Pr...were extremely active in blocking the same cell ta...
...ro, Cipro. That's been the mantra of the media as ...ds who weren't -- clamor for the potent antibiotic...eaper and widely available medications can be used... penicillin. Although alternatives exist, Cipro is...
...ental anti-cancer drug has shown effectiveness in ...o a new report. Researchers say the drug probably ...seful for treating other types of cancer. Dr. Anto...esda, Maryland, and colleagues tested the drug, de...
Other Medicine News:
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: